Paxlovid(TM) Information From FDA and Guidance for AES Members

This American Epilepsy Society (AES) official statement provides information and preliminary guidance to Society members related to the U.S. Food & Drug Administration (FDA) December 22, 2021 Emergency Use Authorization for Paxlovid™ for the oral treatment of mild to moderate COVID-19 in adults...

Descripción completa

Detalles Bibliográficos
Autores principales: Cokley, Jon A., Gidal, Barry E., Keller, Joy A., Vossler, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Official Comments by AES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684591/
https://www.ncbi.nlm.nih.gov/pubmed/36451851
http://dx.doi.org/10.1177/15357597221088415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684591/
https://www.ncbi.nlm.nih.gov/pubmed/36451851
http://dx.doi.org/10.1177/15357597221088415

Ejemplares similares